These results are in good agreement with the clinical reports that the majority of 177Lu-PSMA-617 was eliminated by urine (approximately 50%) and only 1–5% by fecal excretion in patients with PSMA-positive tumor phenotype9. Here, FOLH1 is linked to neoplasm.